Halozyme Therapeutics (HALO) Trading Down 6.5%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares traded down 6.5% during mid-day trading on Thursday . The stock traded as low as $17.04 and last traded at $17.06. 1,198,057 shares were traded during mid-day trading, a decline of 9% from the average session volume of 1,315,554 shares. The stock had previously closed at $18.24.

Several research analysts have recently issued reports on the company. Zacks Investment Research lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th. Deutsche Bank set a $21.00 target price on Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 24th. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $20.00 target price for the company. Finally, BMO Capital Markets upped their price target on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $19.25.

The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. The stock has a market cap of $2,428.61, a P/E ratio of -25.25 and a beta of 1.99.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.04). The company had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The business’s quarterly revenue was up 100.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.23) EPS. equities analysts expect that Halozyme Therapeutics, Inc. will post 0.26 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. boosted its stake in Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 940 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Halozyme Therapeutics by 4.4% during the 2nd quarter. Alliancebernstein L.P. now owns 176,694 shares of the biopharmaceutical company’s stock valued at $2,265,000 after purchasing an additional 7,500 shares during the last quarter. Teachers Advisors LLC boosted its stake in Halozyme Therapeutics by 7.5% during the 2nd quarter. Teachers Advisors LLC now owns 204,786 shares of the biopharmaceutical company’s stock valued at $2,625,000 after purchasing an additional 14,284 shares during the last quarter. BlackRock Inc. boosted its stake in Halozyme Therapeutics by 4.8% during the 2nd quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock valued at $148,652,000 after purchasing an additional 532,658 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in Halozyme Therapeutics by 5.3% during the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 705 shares during the last quarter. Institutional investors own 84.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/10/halozyme-therapeutics-halo-trading-down-6-5.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply